Follow the 제이브이엠 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 제이브이엠 has published 26 insider filings. Market capitalisation: €267.8bn. The latest transaction was reported on 13 March 2026 (Other). Among the most active insiders: 김상욱. All data is openly available.
20
Insider Decl.
n/a
Thresholds
n/a
16 ops.
Buy Volume
n/a
1 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,243 of 28,169 companies
75.8
score / 100
Value
81
Quality
71
FCF yld8.9%
Earn yld9.9%
EV/EBITDA7.6x
ROE13%
Gross mgn41%
Net mgn16%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
제이브이엠 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development and commercialization of pharmaceutical products.